IL-23 in axial spondyloarthritis and psoriatic arthritis : a good fit for biological treatment?
INTRODUCTION: Interleukin 23 (IL-23) is a pro-inflammatory cytokine that plays a protective role against bacterial and fungal infections. However, the dysregulation of the IL-23/IL-17 axis provides a solid substrate for the development of various inflammatory diseases, such as psoriatic arthritis (PsA) and ankylosing spondylitis (AS).
AREAS COVERED: In different clinical trials, several drugs against IL-23 have shown efficacy and safety toward PsA, with excellent results on skin and joint scores. However, the same drugs did not show the same efficacy in AS, suggesting that IL-23 may not be a relevant driver of the pathobiology and clinical symptoms of active axial spondyloarthritis (axSpA).
EXPERT OPINION: These drugs have shown an excellent efficacy and a good safety profile toward PsA, while in AS the efficacy of the IL-23 blockade is lacking for reasons not yet known. Several hypotheses have been reported, but further studies will be needed for a greater understanding. This suggests the involvement of pathways or mechanisms for the development of SpA that remain unknown. In order to allow a wide use of IL-23 inhibitors, further clinical trials and long-term prospective studies are necessary.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Expert opinion on biological therapy - 22(2022), 7 vom: 12. Juli, Seite 843-853 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Atzeni, Fabiola [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-IL-23 drugs |
|---|
| Anmerkungen: |
Date Completed 21.07.2022 Date Revised 15.09.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/14712598.2022.2090834 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM342440373 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM342440373 | ||
| 003 | DE-627 | ||
| 005 | 20231226014123.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14712598.2022.2090834 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1141.xml |
| 035 | |a (DE-627)NLM342440373 | ||
| 035 | |a (NLM)35722768 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Atzeni, Fabiola |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a IL-23 in axial spondyloarthritis and psoriatic arthritis |b a good fit for biological treatment? |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.07.2022 | ||
| 500 | |a Date Revised 15.09.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Interleukin 23 (IL-23) is a pro-inflammatory cytokine that plays a protective role against bacterial and fungal infections. However, the dysregulation of the IL-23/IL-17 axis provides a solid substrate for the development of various inflammatory diseases, such as psoriatic arthritis (PsA) and ankylosing spondylitis (AS) | ||
| 520 | |a AREAS COVERED: In different clinical trials, several drugs against IL-23 have shown efficacy and safety toward PsA, with excellent results on skin and joint scores. However, the same drugs did not show the same efficacy in AS, suggesting that IL-23 may not be a relevant driver of the pathobiology and clinical symptoms of active axial spondyloarthritis (axSpA) | ||
| 520 | |a EXPERT OPINION: These drugs have shown an excellent efficacy and a good safety profile toward PsA, while in AS the efficacy of the IL-23 blockade is lacking for reasons not yet known. Several hypotheses have been reported, but further studies will be needed for a greater understanding. This suggests the involvement of pathways or mechanisms for the development of SpA that remain unknown. In order to allow a wide use of IL-23 inhibitors, further clinical trials and long-term prospective studies are necessary | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a anti-IL-23 drugs | |
| 650 | 4 | |a axial spondyloarthritis | |
| 650 | 4 | |a interleukin 23 | |
| 650 | 4 | |a psoriatic arthritis | |
| 650 | 7 | |a Interleukin-23 |2 NLM | |
| 700 | 1 | |a Siragusano, Cesare |e verfasserin |4 aut | |
| 700 | 1 | |a Masala, Ignazio Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Antonio, Carriero |e verfasserin |4 aut | |
| 700 | 1 | |a Valentina, Picerno |e verfasserin |4 aut | |
| 700 | 1 | |a D'Angelo, Salvatore |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on biological therapy |d 2001 |g 22(2022), 7 vom: 12. Juli, Seite 843-853 |w (DE-627)NLM116190124 |x 1744-7682 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2022 |g number:7 |g day:12 |g month:07 |g pages:843-853 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14712598.2022.2090834 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2022 |e 7 |b 12 |c 07 |h 843-853 | ||